TZTheoklis E. Zaoutis

Theoklis E. Zaoutis

*This is an algorithmically generated author record based on publicly available information.

Theoklis E. Zaoutis has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Antifungal Use in Pediatric Hematology–Oncology and Bone Marrow Transplantation Units in Greece

    by Maria Kourti, Loizos Petrikkos, Elias Iosifidis, Ioannis Kopsidas, Eleni Kourkouni, Kondylia Antoniadi, Lambrini Damianidou, Aikaterini Kaisari, Anna Kontogeorgou, Smaragda Papachristidou, et al.

    Background: Invasive fungal disease remains a major cause of morbidity and mortality among children with malignancies and those undergoing hematopoietic stem cell transplantation (HSCT). Real-world data that describe antifungal prescribing practices in pediatric hematology–oncology units are very limited. Methods: A national prospective observational study from June 2016 through December 2019 in 5 pediatric hematology–oncology units and the single pediatric HSCT unit in Greece was conducted. The first 15 children per month admitted to these units who required initiation of new antifungal agents for prophylaxis or treatment were recorded. Demographics, presence of a central venous line, type of underlying disease, absolute neutrophil count on the first day of antifungal therapy, presence of invasive fungal disease, days of therapy, microbiologic findings and outcomes were recorded. Results: Among 1838 anti-infective courses, 737 (40.1%) involved antifungal agents. Antifungal use was predominantly prophylactic (47.6%) or empiric (50.7%), with targeted therapy accounting for only 1.5%. Prophylaxis was more common in the HSCT unit, whereas empiric therapy predominated in pediatric hematology–oncology units. Fluconazole was the most frequently used prophylactic agent, followed by micafungin and voriconazole. Proven fungemia was uncommon; Candida albicans was the most frequently isolated pathogen. Overall mortality was 1.8%, with slightly higher mortality among patients receiving antifungal therapy. Conclusions: Antifungal use in pediatric oncology and HSCT settings was extensive and heterogeneous, characterized by heavy reliance on prophylactic and empiric strategies and minimal targeted therapy. These findings support the need for structured antifungal stewardship programs to optimize antifungal exposure while preserving favorable outcomes.

  • Open Access

    The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium

    by Dimitrios Poulimeneas, Markela Koniordou, Dimitra Kousi, Christina Merakou, Ioannis Kopsidas, Grammatiki Christina Tsopela, Christos D. Argyropoulos, Sophia C. Themistocleous, George Shiamakkides, Marinos Constantinou, et al.

    Underserved and hard-to-reach population groups are under-represented in vaccine trials. Thus, we aimed to identify the challenges of vaccine trial participation of these groups in member countries of the VACCELERATE network. Seventeen National Coordinators (NC), each representing their respective country (15 European countries, Israel, and Turkey), completed an online survey. From 15 eligible groups, those that were more frequently declared underserved/hard-to-reach in vaccine research were ethnic minorities (76.5%), persons experiencing homelessness (70.6%), illegal workers and refugees (64.7%, each). When prioritization for education on vaccine trials was considered, ethnic groups, migrants, and immigrants (5/17, 29.4%) were the groups most frequently identified by the NC as top targets. The most prominent barriers in vaccine trial participation affecting all groups were low levels of health literacy, reluctance to participate in trials due to engagement level, and low levels of trust in vaccines/vaccinations. This study highlighted population groups considered underserved/hard-to-reach in countries contained within the European region, and the respective barriers these groups face when participating in clinical studies. Our findings aid with the design of tailored interventions (within—and across—countries of the European region) and with the development of strategies to overcome major barriers in phase 2 and phase 3 vaccine trial participation.